Table 2. Summary of finding form Pirfenidone for idiopathic pulmonary fibrosis.
1: Non primary outcome from RCTs, 2: High heterogeneity; 6MWT: Six minutes walk test; RCT: Randomized controlled trial; RR: Risk ratio; CI: confidence interval
| Outcomes | Anticipate absolute effects (Study population) (95% CI) | Relative Effect | NO of participants | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
| Risk with placebo | Risk with Pirfenidone | ||||
| All cause-mortality | 67 per 1000 | 36 per 1000 (22 to 59) | RR 0.53 (0.32 to 0.88) | 1247 (3 RCTs) | ⨁⨁⨁◯MODERATE1 |
| Progression free-survival | 442 per 1000 | 372 per 1000 (332 to 416) | RR 0.82 (0.73 to 0.92) | 1514 (4 RCTs) | ⨁⨁⨁◯MODERATE1 |
| Acute exacerbation | 26 per 1000 | 15 per 1000 (5 to 47) | RR 0.59 (0.19 to 1.84) | 374 (2 RCTs) | ⨁⨁◯◯LOW1,2 |
| Worsening of IPF | 168 per 1000 | 107 per 1000 (84 to 139) | RR 0.64 (0.50 to 0.83) | 1621 (5 RCTs) | ⨁⨁⨁◯MODERATE1 |
| Change on 6MWT | 417 per 1000 | 308 per 1000 (267 to 358) | RR 0.74 (0.64 to 0.86) | 1236 (3 RCTs) | ⨁⨁⨁⨁HIGH |
| Change on aminotransferases | 30 per 1000 | 68 per 1000 (40 to 115) | RR 2.26 (1.33 to 3.83) | 1621 (5 RCTs) | ⨁⨁⨁◯MODERATE1 |